WO2004006955A1 - Super humanized antibodies - Google Patents
Super humanized antibodies Download PDFInfo
- Publication number
- WO2004006955A1 WO2004006955A1 PCT/US2002/022011 US0222011W WO2004006955A1 WO 2004006955 A1 WO2004006955 A1 WO 2004006955A1 US 0222011 W US0222011 W US 0222011W WO 2004006955 A1 WO2004006955 A1 WO 2004006955A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- human
- sequences
- antibody
- cdr
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK02752269.7T DK1539233T3 (en) | 2002-07-12 | 2002-07-12 | Humanized super-antibodies |
ES02752269T ES2370225T3 (en) | 2002-07-12 | 2002-07-12 | SUPERHUMANIZED ANTIBODIES. |
AT02752269T ATE506966T1 (en) | 2002-07-12 | 2002-07-12 | HUMANIZED SUPER ANTIBODIES |
CN02829598.6A CN1671416B (en) | 2001-07-12 | 2002-07-12 | Super humanized antibodies |
IL16624402A IL166244A0 (en) | 2001-07-12 | 2002-07-12 | Super humanized antibodies |
EP02752269A EP1539233B1 (en) | 2001-07-12 | 2002-07-12 | Super humanized antibodies |
US10/194,975 US6881557B2 (en) | 2001-07-12 | 2002-07-12 | Super humanized antibodies |
AU2002368077A AU2002368077B2 (en) | 2001-07-12 | 2002-07-12 | Super humanized antibodies |
MXPA05000511A MXPA05000511A (en) | 2001-07-12 | 2002-07-12 | Super humanized antibodies. |
CA2491864A CA2491864C (en) | 2001-07-12 | 2002-07-12 | Super humanized antibodies |
EP10185475A EP2298809A3 (en) | 2001-07-12 | 2002-07-12 | Super humanized antibodies |
PCT/US2002/022011 WO2004006955A1 (en) | 2001-07-12 | 2002-07-12 | Super humanized antibodies |
JP2004521391A JP2005538706A (en) | 2001-07-12 | 2002-07-12 | Super humanized antibody |
DE60239895T DE60239895D1 (en) | 2002-07-12 | 2002-07-12 | HUMANIZED SUPER ANTIBODIES |
US11/054,669 US7732578B2 (en) | 2001-07-12 | 2005-02-08 | Super humanized antibodies |
US11/432,734 US7709226B2 (en) | 2001-07-12 | 2006-05-10 | Method of humanizing antibodies by matching canonical structure types CDRs |
US12/749,257 US20110137014A1 (en) | 2001-07-12 | 2010-03-29 | Super humanized antibodies |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30511101P | 2001-07-12 | 2001-07-12 | |
PCT/US2002/022011 WO2004006955A1 (en) | 2001-07-12 | 2002-07-12 | Super humanized antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004006955A1 true WO2004006955A1 (en) | 2004-01-22 |
Family
ID=43602927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/022011 WO2004006955A1 (en) | 2001-07-12 | 2002-07-12 | Super humanized antibodies |
Country Status (9)
Country | Link |
---|---|
US (4) | US6881557B2 (en) |
EP (2) | EP1539233B1 (en) |
JP (1) | JP2005538706A (en) |
CN (1) | CN1671416B (en) |
AU (1) | AU2002368077B2 (en) |
CA (1) | CA2491864C (en) |
IL (1) | IL166244A0 (en) |
MX (1) | MXPA05000511A (en) |
WO (1) | WO2004006955A1 (en) |
Cited By (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005112564A2 (en) * | 2004-04-15 | 2005-12-01 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Germline and sequence variants of humanized antibodies and methods of making and using them |
WO2006055778A2 (en) | 2004-11-16 | 2006-05-26 | Kalobios, Inc. | Immunoglobulin variable region cassette exchange |
WO2006096653A2 (en) * | 2005-03-04 | 2006-09-14 | Biogen Idec Ma Inc. | Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues |
WO2007068750A2 (en) | 2005-12-16 | 2007-06-21 | Glaxo Group Limited | Immunoglobulins directed against nogo |
WO2007137984A2 (en) | 2006-05-25 | 2007-12-06 | Glaxo Group Limited | Modified humanised anti-interleukin-18 antibodies |
WO2008017126A1 (en) | 2006-08-11 | 2008-02-14 | Csl Limited | Treatment of pulmonary disease conditions |
JP2009502171A (en) * | 2005-07-25 | 2009-01-29 | トゥルビオン・ファーマシューティカルズ・インコーポレーテッド | Reduction of B cells using CD37-specific and CD20-specific binding molecules |
EP2050765A1 (en) * | 2007-10-19 | 2009-04-22 | Centocor, Inc. | Methods for use in human-adapting monoclonal antibodies |
US7575893B2 (en) | 2003-01-23 | 2009-08-18 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
WO2010070094A1 (en) | 2008-12-19 | 2010-06-24 | Glaxo Group Limited | Myostatin binding proteins |
JP2010533495A (en) * | 2007-07-16 | 2010-10-28 | ジェネンテック, インコーポレイテッド | Humanized CD79b antibodies and immunoconjugates and their use |
US7855276B2 (en) | 2004-12-30 | 2010-12-21 | The United States Of America As Represented By The Department Of Health And Human Services | Framework residue substituted humanized COL-1 antibodies and their use |
WO2011076883A1 (en) | 2009-12-23 | 2011-06-30 | 4-Antibody Ag | Binding members for human cytomegalovirus |
US7981843B2 (en) | 2004-01-20 | 2011-07-19 | Kalobios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
WO2011094259A2 (en) | 2010-01-28 | 2011-08-04 | Glaxo Group Limited | Cd127 binding proteins |
WO2011107480A1 (en) | 2010-03-03 | 2011-09-09 | Glaxo Group Limited | Antigen binding proteins specific for serum amyloid p component |
WO2011151432A1 (en) | 2010-06-03 | 2011-12-08 | Glaxo Group Limited | Humanised antigen binding proteins to myostatin6 |
EP2404935A1 (en) | 2004-03-30 | 2012-01-11 | Glaxo Group Limited | Immunoglobulin binding HOSM |
EP2423229A1 (en) | 2006-03-27 | 2012-02-29 | Medimmune Limited | Binding member for GM-CSF receptor |
WO2012085015A1 (en) | 2010-12-20 | 2012-06-28 | Medimmune Limited | Anti-il-18 antibodies and their uses |
WO2012069433A3 (en) * | 2010-11-23 | 2012-08-09 | Glaxo Group Limited | Antigen binding proteins to oncostatin m (osm) |
US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
EP2530090A2 (en) | 2006-10-19 | 2012-12-05 | CSL Limited | Anti-IL-13R alpha 1 antibodies and their uses thereof |
WO2013053767A1 (en) | 2011-10-10 | 2013-04-18 | Medimmune Limited | Treatment for rheumatoid arthritis |
WO2013096380A2 (en) | 2011-12-20 | 2013-06-27 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
EP2620452A1 (en) | 2007-02-15 | 2013-07-31 | Medimmune Limited | Binding members for IGE molecules |
EP2628751A2 (en) | 2006-11-30 | 2013-08-21 | AstraZeneca AB | Binding members for interleukin-6 and use thereof |
WO2014006105A1 (en) | 2012-07-05 | 2014-01-09 | Glaxo Group Limited | Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis |
WO2014072306A1 (en) | 2012-11-08 | 2014-05-15 | F. Hoffmann-La Roche Ag | Her3 antigen binding proteins binding to the beta-hairpin of her3 |
WO2015179435A1 (en) | 2014-05-19 | 2015-11-26 | Bayer Healthcare Llc | Optimized humanized monoclonal antibodies against activated protein c and uses thereof |
WO2016001140A1 (en) | 2014-06-30 | 2016-01-07 | Affiris Ag | Vaccines and monoclonal antibodies targeting truncated variants of osteopontin and uses thereof |
WO2016059602A2 (en) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
WO2016092524A1 (en) | 2014-12-11 | 2016-06-16 | Inbiomotion S.L. | Binding members for human c-maf |
KR20160116056A (en) | 2008-08-14 | 2016-10-06 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | Anti-il-12/il-23 antibodies |
WO2017158064A1 (en) | 2016-03-15 | 2017-09-21 | Astrazeneca Ab | Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US9969814B2 (en) | 2010-02-08 | 2018-05-15 | Regeneron Pharmaceuticals, Inc. | Methods for making fully human bispecific antibodies using a common light chain |
WO2018170351A1 (en) | 2017-03-16 | 2018-09-20 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and uses thereof |
US10130081B2 (en) | 2011-08-05 | 2018-11-20 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
US10143186B2 (en) | 2010-02-08 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
WO2019025299A1 (en) | 2017-07-31 | 2019-02-07 | F. Hoffmann-La Roche Ag | Three-dimensional structure-based humanization method |
US10406197B2 (en) | 2014-07-10 | 2019-09-10 | Affiris Ag | Substances and methods for the use in prevention and/or treatment in Huntington's disease |
US10494432B2 (en) | 2007-07-16 | 2019-12-03 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
US10544218B2 (en) | 2008-01-31 | 2020-01-28 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
EP3434690A4 (en) * | 2016-03-23 | 2020-04-01 | Seoul National University R&DB Foundation | Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus, and use for same |
US10633435B2 (en) | 2018-03-05 | 2020-04-28 | Janssen Pharmaceutica Nv | Anti-PHF-tau antibodies and uses thereof |
EP3721942A1 (en) | 2012-10-15 | 2020-10-14 | Medimmune Limited | Antibodies to amyloid beta |
US10881085B2 (en) | 2014-03-21 | 2021-01-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
US11000510B2 (en) | 2014-09-23 | 2021-05-11 | Genentech, Inc. | Methods of using anti-CD79b immunoconjugates |
US11111314B2 (en) | 2015-03-19 | 2021-09-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
US11186638B2 (en) | 2011-09-12 | 2021-11-30 | Genzyme Corporation | Anti-αβTCR antibody |
WO2022201122A1 (en) | 2021-03-26 | 2022-09-29 | Janssen Biotech, Inc. | Humanized antibodies against paired helical filament tau and uses thereof |
US11697690B2 (en) | 2014-03-19 | 2023-07-11 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
US11807690B2 (en) | 2013-03-11 | 2023-11-07 | Genzyme Corporation | Hyperglycosylated binding polypeptides |
Families Citing this family (395)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
MXPA05000511A (en) * | 2001-07-12 | 2005-09-30 | Jefferson Foote | Super humanized antibodies. |
ITMI20021527A1 (en) * | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | C5 COMPONENT ANTIBODIES OF COMPLEMENT AND THEIR USE |
US6875433B2 (en) * | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
TWI382031B (en) * | 2003-07-15 | 2013-01-11 | Amgen Inc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
US20050033031A1 (en) * | 2003-08-07 | 2005-02-10 | Couto Fernando Jose Rebelo Do | Methods for humanizing rabbit monoclonal antibodies |
US20050042664A1 (en) * | 2003-08-22 | 2005-02-24 | Medimmune, Inc. | Humanization of antibodies |
US7046714B2 (en) * | 2003-09-10 | 2006-05-16 | Intel Corporation | Method and apparatus for Raman ring resonator based laser/wavelength converter |
SI2380911T1 (en) * | 2003-11-05 | 2018-07-31 | Roche Glycart Ag | Antigen binding molecules with increased Fc receptor binding affinity and effector function |
WO2005047328A2 (en) * | 2003-11-07 | 2005-05-26 | Curagen Corporation | Antibodies against secretoryleukocyte protease inhibitor |
AR046833A1 (en) | 2003-11-10 | 2005-12-28 | Schering Corp | ANTI-INTERLEUQUINA ANTIBODIES-10 |
AU2005214988A1 (en) * | 2004-02-17 | 2005-09-01 | Absalus, Inc. | Super-humanized antibodies against respiratory syncytial virus |
ES2527292T3 (en) | 2004-03-31 | 2015-01-22 | Genentech, Inc. | Humanized anti-TGF-beta antibodies |
ME00226B (en) | 2004-07-15 | 2011-02-10 | Medarex Llc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
WO2006036568A2 (en) * | 2004-09-13 | 2006-04-06 | Arrowsmith Technologies Llp | Antibody buffering of a ligand in vivo |
CN101076542A (en) * | 2004-09-13 | 2007-11-21 | 伊沃詹尼克斯有限公司 | Antibodies specific for hepatocellular carcinoma and other carcinomas and uses thereof |
AU2006211037B2 (en) | 2005-02-07 | 2012-05-24 | Roche Glycart Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
US20060223096A1 (en) * | 2005-03-25 | 2006-10-05 | Glycart Biotechnology Ag | Antigen binding molecules directed to MCSP and having increased Fc receptor binding affinity and effector function |
MX2007013924A (en) * | 2005-05-09 | 2008-01-28 | Glycart Biotechnology Ag | Antigen binding molecules having modified fc regions and altered binding to fc receptors. |
JP5252635B2 (en) * | 2005-07-01 | 2013-07-31 | メダレックス インコーポレーティッド | Human monoclonal antibody against programmed death ligand 1 (PD-L1) |
AU2006281980A1 (en) * | 2005-08-15 | 2007-02-22 | Cephalon Australia Pty Ltd | Engineered antibodies with new world primate framework regions |
NO345919B1 (en) | 2005-08-26 | 2021-10-18 | Roche Glycart Ag | Modified antigen-binding molecules with altered cell signaling activity |
US7981414B2 (en) * | 2005-12-20 | 2011-07-19 | Cephalon Australia Pty Ltd | Anti-inflammatory dAb |
NZ569988A (en) * | 2006-02-01 | 2011-09-30 | Cephalon Australia Pty Ltd | Domain antibody construct which binds to human TNF-alpha and contains a modified hinge region sequence and a truncated CH1 domain |
MX2008015138A (en) * | 2006-06-02 | 2009-01-28 | Aveo Pharmaceuticals Inc | Hepatocyte growth factor (hgf) binding proteins. |
JP4686634B2 (en) | 2006-06-02 | 2011-05-25 | アベオ ファーマシューティカルズ, インコーポレイテッド | Hepatocyte growth factor (HGF) binding protein |
MX2008015524A (en) * | 2006-06-12 | 2009-01-13 | Trubion Pharmaceuticals Inc | Single-chain multivalent binding proteins with effector function. |
AR062223A1 (en) * | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | MOLECULES OF ADHESION TO THE ANTIGEN THAT ADHER TO EGFR, VECTORS THAT CODE THEM, AND THEIR USES OF THESE |
CL2007002567A1 (en) | 2006-09-08 | 2008-02-01 | Amgen Inc | ISOLATED PROTEINS FROM LINK TO ACTIVINE TO HUMAN. |
SI2094728T1 (en) * | 2006-10-26 | 2013-06-28 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
KR20150067395A (en) * | 2006-12-01 | 2015-06-17 | 메다렉스, 엘.엘.시. | Human antibodies that bind cd22 and uses thereof |
US20080139790A1 (en) * | 2006-12-08 | 2008-06-12 | Jennings Philip A | Chimeric antibodies |
WO2008079466A1 (en) | 2006-12-20 | 2008-07-03 | Mmr Information Systems, Inc. | Antibodies and methods for making and using them |
US20100291024A1 (en) * | 2007-03-30 | 2010-11-18 | Xuebin Qin | Methods and compositions for the treatment of proliferative and pathogenic diseases |
WO2008137066A1 (en) * | 2007-05-02 | 2008-11-13 | The Board Of Regents Of The University Of Oklahoma | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases |
TW200911835A (en) * | 2007-06-08 | 2009-03-16 | Irm Llc | Methods and compositions for inducing apoptosis in cancer cells |
US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
US20100248971A1 (en) * | 2007-12-03 | 2010-09-30 | Takashi Inagaki | Process for antibody production |
AR070141A1 (en) * | 2008-01-23 | 2010-03-17 | Glenmark Pharmaceuticals Sa | SPECIFIC HUMANIZED ANTIBODIES FOR VON WILLEBRAND FACTOR |
SI2132228T1 (en) | 2008-04-11 | 2011-10-28 | Emergent Product Dev Seatle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
KR20110043786A (en) * | 2008-08-20 | 2011-04-27 | 센토코 오르토 바이오테크 인코포레이티드 | Engineered anti-il-13 antibodies, compositions, methods and uses |
EP3889265A1 (en) | 2008-09-30 | 2021-10-06 | Ablexis, LLC | Transgenic mice for the production of chimeric antibodies |
US20100261620A1 (en) * | 2008-10-14 | 2010-10-14 | Juan Carlos Almagro | Methods of Humanizing and Affinity-Maturing Antibodies |
US8101723B2 (en) | 2008-11-07 | 2012-01-24 | Galaxy Biotech, Llc | Monoclonal antibodies to fibroblast growth factor receptor 2 |
CN102271708A (en) * | 2008-11-13 | 2011-12-07 | 新兴产品开发西雅图有限公司 | CD37 immunotherapeutic combination therapies and uses thereof |
KR20110129935A (en) * | 2009-03-16 | 2011-12-02 | 세파론 오스트레일리아 피티와이 엘티디 | Humanised antibodies with anti-tumour activity |
US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
JP5925678B2 (en) * | 2009-08-18 | 2016-05-25 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Methods and compositions for the treatment of proliferative and pathogenic diseases |
WO2011054030A1 (en) * | 2009-11-05 | 2011-05-12 | Cephalon Australia Pty Ltd | Treatment of cancer involving mutated kras or braf genes |
DK2504363T3 (en) | 2009-11-24 | 2019-07-29 | Alethia Biotherapeutics Inc | ANTI-CLUSTERIN ANTIBODIES AND ANTI-BINDING FRAGMENTS AND THEIR USE TO REDUCE TUMOR VOLUME |
KR101553244B1 (en) | 2009-12-10 | 2015-09-15 | 리제너론 파마슈티칼스 인코포레이티드 | Mice that make heavy chain antibodies |
US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
US20120021409A1 (en) * | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
US9011861B2 (en) * | 2010-02-25 | 2015-04-21 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
KR102004106B1 (en) | 2010-03-31 | 2019-07-25 | 아블렉시스, 엘엘씨 | Genetic Engineering of non-human animals for the production of chimeric antibodies |
NZ603045A (en) * | 2010-04-07 | 2014-11-28 | Abbvie Inc | Tnf-alpha binding proteins |
EP2560994B1 (en) | 2010-04-08 | 2016-10-12 | JN Biosciences LLC | Antibodies to cd122 |
SG184452A1 (en) | 2010-04-09 | 2012-11-29 | Aveo Pharmaceuticals Inc | Anti-erbb3 antibodies |
WO2011156617A2 (en) | 2010-06-09 | 2011-12-15 | Aveo Pharmaceuticals, Inc. | Anti-egfr antibodies |
WO2012003472A1 (en) | 2010-07-02 | 2012-01-05 | Aveo Pharmaceuticals, Inc. | Anti-notch1 antibodies |
JP2013533746A (en) | 2010-07-06 | 2013-08-29 | アベオ ファーマシューティカルズ, インコーポレイテッド | Anti-RON antibody |
WO2012009760A1 (en) | 2010-07-20 | 2012-01-26 | Cephalon Australia Pty Ltd | Anti-il-23 heterodimer specific antibodies |
NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
EP2606152B1 (en) | 2010-08-18 | 2016-10-05 | Fred Hutchinson Cancer Research Center | Methods for determining the presence or risk of developing facioscapulohumeral dystrophy (fshd) |
PT3156420T (en) | 2010-12-06 | 2019-05-27 | Seattle Genetics Inc | Humanized antibodies to liv-1 and use of same to treat cancer |
JP6147670B2 (en) | 2010-12-22 | 2017-06-14 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | Modified antibodies with improved half-life |
JOP20210044A1 (en) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | Anti-cd38 antibodies |
US9683054B2 (en) * | 2010-12-31 | 2017-06-20 | BioAlta, LLC | Express humanization of antibodies |
ES2865068T3 (en) | 2011-01-14 | 2021-10-14 | Univ California | Therapeutic antibodies to ROR-1 protein and methods of using them |
WO2012103165A2 (en) | 2011-01-26 | 2012-08-02 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
US9206257B2 (en) | 2011-04-19 | 2015-12-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
WO2012175735A1 (en) | 2011-06-23 | 2012-12-27 | Vib Vzw | A20 inhibitors for the treatment of respiratory viral infections |
DK2739310T3 (en) | 2011-08-05 | 2018-07-16 | Res Found Dev | Improved methods and compositions for modulating OLFML3-mediated angiogenesis |
GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
CN104114577A (en) | 2011-09-30 | 2014-10-22 | 特瓦制药澳大利亚私人有限公司 | Antibodies against TL1a and uses thereof |
WO2013059885A2 (en) | 2011-10-28 | 2013-05-02 | Cephalon Australia Pty Ltd | Polypeptide constructs and uses thereof |
JP2015504413A (en) | 2011-10-28 | 2015-02-12 | パトリス リミテッド | PAT-LM1 epitope and methods for using the same |
CN104334184B (en) | 2011-10-28 | 2017-12-29 | 普罗典娜生物科学有限公司 | Identify the humanized antibody of α synapse nucleoproteins |
WO2013092998A1 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of antibodies |
AU2013208007A1 (en) | 2012-01-09 | 2014-07-31 | The Scripps Research Institute | Humanized antibodies with ultralong CDR3 |
AU2013211874B2 (en) | 2012-01-27 | 2017-11-02 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
US9546219B2 (en) | 2012-02-08 | 2017-01-17 | North Carolina State University | Treatment of allergic diseases with recombinant antibodies |
WO2013125221A1 (en) * | 2012-02-21 | 2013-08-29 | 静岡県 | Affinity ligand for antibody purification |
CN104159611A (en) | 2012-02-22 | 2014-11-19 | 阿莱斯亚生物疗法股份有限公司 | Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer |
US9441039B2 (en) | 2012-05-07 | 2016-09-13 | Amgen Inc. | Anti-erythropoietin antibodies |
US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
KR20150023535A (en) * | 2012-06-05 | 2015-03-05 | 리제너론 파마슈티칼스 인코포레이티드 | Methods for making fully human bispecific antibodies using a common light chain |
WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
US10132799B2 (en) | 2012-07-13 | 2018-11-20 | Innate Pharma | Screening of conjugated antibodies |
KR102268351B1 (en) | 2012-07-25 | 2021-06-22 | 셀덱스 쎄라퓨틱스, 인크. | Anti-kit antibodies and uses thereof |
UA115789C2 (en) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Antibody formulations and uses thereof |
UA118441C2 (en) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Antibodies recognizing alpha-synuclein |
WO2014066590A1 (en) | 2012-10-24 | 2014-05-01 | Research Development Foundation | Jam-c antibodies and methods for treatment of cancer |
EP2912194B1 (en) | 2012-10-26 | 2019-05-08 | Memorial Sloan-Kettering Cancer Center | Androgen receptor variants and methods for making and using |
WO2014072482A1 (en) | 2012-11-09 | 2014-05-15 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
DK2935330T3 (en) | 2012-12-19 | 2019-07-22 | Aveo Pharmaceuticals Inc | ANTI-NOTCH3 ANTIBODIES |
EP3689370A1 (en) | 2012-12-21 | 2020-08-05 | Aveo Pharmaceuticals Inc. | Anti-gdf15 antibodies |
MX2015008534A (en) | 2012-12-26 | 2017-07-04 | Oncosynergy Inc | ANTI- INTEGRIN ß1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF. |
CA2899960C (en) | 2013-02-01 | 2022-05-03 | Transbio Ltd | Anti-cd83 antibodies and use thereof |
KR20150136061A (en) | 2013-02-01 | 2015-12-04 | 산타 마리아 바이오테라퓨틱스, 인코포레이티드 | Administration of an anti-activin-a compound to a subject |
PT2953971T (en) | 2013-02-07 | 2023-05-02 | Csl Ltd | Il-11r binding proteins and uses thereof |
WO2014164301A2 (en) | 2013-03-11 | 2014-10-09 | Amgen Inc. | Protein formulations |
MX2015012225A (en) | 2013-03-13 | 2016-01-08 | Prothena Biosciences Ltd | Tau immunotherapy. |
WO2014143886A2 (en) * | 2013-03-15 | 2014-09-18 | Edimer Pharmaceuticals, Inc. | Anti-ectodysplasin antibodies |
WO2014151834A2 (en) | 2013-03-15 | 2014-09-25 | Amgen Inc. | Methods and compositions relating to anti-ccr7 antigen binding proteins |
EP2968582B1 (en) | 2013-03-15 | 2020-07-01 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
RS57840B1 (en) | 2013-03-18 | 2018-12-31 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
CN110526971B (en) | 2013-04-29 | 2023-06-30 | 泰华制药澳大利亚公司 | anti-CD 38 antibodies and fusions with attenuated interferon alpha-2B |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
EP3010547B1 (en) | 2013-06-20 | 2021-04-21 | Innate Pharma | Enzymatic conjugation of polypeptides |
KR20160042871A (en) | 2013-06-21 | 2016-04-20 | 이나뜨 파르마, 에스.아. | Enzymatic conjugation of polypeptides |
CA2916465C (en) * | 2013-06-24 | 2023-05-23 | Neximmune | Humanized anti-cd28 antibodies and artificial antigen presenting cells |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
WO2015004633A1 (en) | 2013-07-12 | 2015-01-15 | Neotope Biosciences Limited | Antibodies that recognize islet-amyloid polypeptide (iapp) |
WO2015004632A1 (en) | 2013-07-12 | 2015-01-15 | Neotope Biosciences Limited | Antibodies that recognize iapp |
CN105814074B (en) * | 2013-07-18 | 2020-04-21 | 图鲁斯生物科学有限责任公司 | Humanized antibodies with ultralong complementarity determining regions |
CN106659909B (en) | 2013-08-21 | 2022-01-11 | 德克萨斯州大学系统董事会 | Compositions and methods for targeting connexin hemichannels |
US10702608B2 (en) | 2013-09-08 | 2020-07-07 | Kodiak Sciences Inc. | Factor VIII zwitterionic polymer conjugates |
US9944697B2 (en) | 2013-11-06 | 2018-04-17 | Jansson Biotech, Inc. | Anti-CCL17 antibodies |
JP2017501848A (en) | 2013-11-19 | 2017-01-19 | プロセナ バイオサイエンシーズ リミテッド | Monitoring immunotherapy of Lewy body disease from constipation symptoms |
RU2718054C2 (en) | 2013-11-28 | 2020-03-30 | СиЭсЭл ЛИМИТЕД | Method of treating nephropathy |
US9321834B2 (en) | 2013-12-05 | 2016-04-26 | Leidos, Inc. | Anti-malarial compositions |
US10919929B2 (en) | 2013-12-11 | 2021-02-16 | Sloan-Kettering Institute For Cancer Research | Glucocorticoid inhibitors for treatment of prostate cancer |
ES2851386T3 (en) | 2013-12-18 | 2021-09-06 | Csl Ltd | Wound treatment method |
TW201623331A (en) | 2014-03-12 | 2016-07-01 | 普羅帝納生物科學公司 | Anti-MCAM antibodies and associated methods of use |
ES2744526T3 (en) | 2014-03-12 | 2020-02-25 | Prothena Biosciences Ltd | Anti-MCAM antibodies and associated methods of use |
WO2015136471A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg1-3 |
CA2938933A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
US20170002077A1 (en) | 2014-03-13 | 2017-01-05 | Prothena Biosciences Limited | Combination treatment for multiple sclerosis |
CA2944402A1 (en) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
US10087259B1 (en) | 2014-04-28 | 2018-10-02 | Memorial Sloan Kettering Cancer Center | Depleting tumor-specific tregs |
UA119352C2 (en) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof |
IL293212B2 (en) | 2014-05-28 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Anti–gitr antibodies and methods of use thereof |
US20170137505A1 (en) | 2014-06-20 | 2017-05-18 | Aveo Pharmaceuticals, Inc. | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
US20170137506A1 (en) | 2014-06-20 | 2017-05-18 | Aveo Pharmaceuticals, Inc. | Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator |
TWI713453B (en) | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | Interferon alpha and omega antibody antagonists |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
JP6913018B2 (en) | 2014-07-08 | 2021-08-04 | ニューヨーク・ユニバーシティ | Tau imaging ligands, and their use in the diagnosis and treatment of tau disorders |
US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
NZ730186A (en) | 2014-09-22 | 2020-04-24 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
EP3851122A1 (en) | 2014-09-25 | 2021-07-21 | Aveo Pharmaceuticals Inc. | Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent |
JP6849590B2 (en) | 2014-10-17 | 2021-03-24 | コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. | Butyrylcholinesterase amphoteric ionic polymer conjugate |
EP3209695A4 (en) | 2014-10-23 | 2018-05-30 | DendroCyte BioTech Pty Ltd | Cd83 binding proteins and uses thereof |
ES2857553T3 (en) * | 2014-10-24 | 2021-09-29 | Hoffmann La Roche | Humanization of antibodies based on VH-VL interdomain angle |
US10544199B2 (en) | 2014-10-29 | 2020-01-28 | Teva Pharmaceuticals Australia Pty Ltd | Interferon alpha 2B variants |
US10155820B2 (en) | 2014-11-12 | 2018-12-18 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
EP3546567A1 (en) | 2014-12-06 | 2019-10-02 | GEMoaB Monoclonals GmbH | Genetic modified pluri- or multipotent stem cells and uses thereof |
US10940212B2 (en) | 2014-12-19 | 2021-03-09 | Monash University | IL-21 agonist antibodies and methods of treatment using same |
WO2016105542A2 (en) | 2014-12-24 | 2016-06-30 | Neximmune, Inc | Nanoparticle compositions and methods for immunotherapy |
AU2015374301B2 (en) | 2014-12-30 | 2021-02-11 | Celgene Corporation | Anti-CD47 antibodies and uses thereof |
TWI769570B (en) | 2015-01-28 | 2022-07-01 | 愛爾蘭商普羅佘納生物科技有限公司 | Anti-transthyretin antibodies |
TWI786505B (en) | 2015-01-28 | 2022-12-11 | 愛爾蘭商普羅佘納生物科技有限公司 | Anti-transthyretin antibodies |
TWI718121B (en) | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | Anti-transthyretin antibodies |
CN115368460A (en) | 2015-03-17 | 2022-11-22 | 纪念斯隆-凯特林癌症中心 | anti-MUC 16 antibodies and uses thereof |
WO2016149535A1 (en) | 2015-03-18 | 2016-09-22 | Seattle Genetics, Inc. | Cd48 antibodies and conjugates thereof |
EP3277725B1 (en) | 2015-03-30 | 2020-11-25 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
US10913798B2 (en) | 2015-04-24 | 2021-02-09 | The Regents Of The University Of California | Modulators of ROR1-ROR2 binding |
JP2018518461A (en) | 2015-04-29 | 2018-07-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Treatment of progressive ossifying fibrodysplasia |
CA2984794A1 (en) | 2015-05-07 | 2016-11-10 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
US10906982B2 (en) | 2015-05-15 | 2021-02-02 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor 2 antibodies |
MA53355A (en) | 2015-05-29 | 2022-03-16 | Agenus Inc | ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF |
TW201709932A (en) | 2015-06-12 | 2017-03-16 | 西雅圖遺傳學公司 | CD123 antibodies and conjugates thereof |
US11351269B2 (en) | 2015-06-30 | 2022-06-07 | Seagen Inc. | Anti-NTB-A antibodies and related compositions and methods |
GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
JO3711B1 (en) | 2015-07-13 | 2021-01-31 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
BR112018002319A2 (en) | 2015-08-05 | 2018-12-11 | Janssen Biotech, Inc. | anti-cd154 antibodies and methods of use |
CN108135986B (en) | 2015-08-13 | 2022-07-29 | 纽约大学 | Antibody-based molecules specific for a truncated Asp421 epitope of Tau and their use in the diagnosis and treatment of Tau disease |
FI3334761T3 (en) | 2015-08-13 | 2023-08-14 | Univ New York | Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy |
KR20220131277A (en) | 2015-09-01 | 2022-09-27 | 아게누스 인코포레이티드 | Anti-pd-1 antibodies and methods of use thereof |
WO2017041004A1 (en) | 2015-09-02 | 2017-03-09 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for modulating t-cell mediated immune response |
WO2017048902A1 (en) | 2015-09-15 | 2017-03-23 | Board Of Regents, The University Of Texas System | T-cell receptor (tcr)-binding antibodies and uses thereof |
WO2017046776A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
WO2017046774A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
UA126278C2 (en) | 2015-09-21 | 2022-09-14 | Аптево Рісьорч Енд Девелопмент Ллс | Cd3 binding polypeptides |
EP3356415B1 (en) | 2015-09-29 | 2024-05-01 | Amgen Inc. | Asgr inhibitors for reduzing cholesterol levels |
CN116333125A (en) | 2015-10-30 | 2023-06-27 | 银河生物技术有限责任公司 | Antibodies that bind death receptor 4 and death receptor 5 |
EP3370769A4 (en) | 2015-11-03 | 2019-05-22 | Janssen Biotech, Inc. | Antibodies specifically binding tim-3 and their uses |
CN108925136B (en) | 2015-12-02 | 2022-02-01 | 斯特赛恩斯公司 | Antibodies specific for glycosylated BTLA (B and T lymphocyte attenuating factor) |
WO2017106684A2 (en) | 2015-12-17 | 2017-06-22 | Janssen Biotech, Inc. | Antibodies specifically binding hla-dr and their uses |
SG11201805420SA (en) | 2015-12-30 | 2018-07-30 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
MX2018008383A (en) | 2016-01-10 | 2019-05-30 | Neotx Therapeutics Ltd | Immunopotentiator enhanced superantigen mediated cancer immunotherapy. |
WO2017143069A1 (en) | 2016-02-17 | 2017-08-24 | Seattle Genetics, Inc. | Bcma antibodies and use of same to treat cancer and immunological disorders |
CA3015839A1 (en) | 2016-02-26 | 2017-08-31 | The Board Of Regents Of The University Of Texas System | Connexin (cx)43 hemichannel-binding antibodies and uses thereof |
WO2017149513A1 (en) | 2016-03-03 | 2017-09-08 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
WO2017153955A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
WO2017153953A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
CN108779180B (en) | 2016-03-23 | 2020-10-16 | 迈博斯生物医药(苏州)有限公司 | Novel anti-PD-L1 antibodies |
CN109195991B (en) | 2016-03-29 | 2023-10-31 | 斯特库比股份有限公司 | Dual function antibodies specific for glycosylated PD-L1 and methods of use thereof |
US20190105403A1 (en) | 2016-03-29 | 2019-04-11 | Stcube & Co., Inc. | Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins |
US10603380B2 (en) | 2016-04-01 | 2020-03-31 | Kite Pharma, Inc. | Chimeric antigen and T cell receptors and methods of use |
HUE060645T2 (en) | 2016-04-01 | 2023-04-28 | Kite Pharma Inc | Chimeric receptors and methods of use thereof |
CU20180120A7 (en) | 2016-04-01 | 2019-05-03 | Kite Pharma Inc | BCMA UNION MOLECULES |
WO2017189483A1 (en) | 2016-04-25 | 2017-11-02 | The Johns Hopkins University | Znt8 assays for drug development and pharmaceutical compositions |
WO2017191561A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
SG11201808434WA (en) | 2016-05-02 | 2018-10-30 | Prothena Biosciences Ltd | Antibodies recognizing tau |
PL3452507T3 (en) | 2016-05-02 | 2023-01-09 | Prothena Biosciences Limited | Tau immunotherapy |
SG11201810023QA (en) | 2016-05-27 | 2018-12-28 | Agenus Inc | Anti-tim-3 antibodies and methods of use thereof |
BR112018074922B1 (en) | 2016-06-02 | 2022-10-25 | Abbvie Inc | GLUCOCORTICOID RECEPTOR AGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING SUCH COMPOUNDS AND THERAPEUTIC USE THEREOF |
WO2017208210A1 (en) | 2016-06-03 | 2017-12-07 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
IL308798A (en) | 2016-06-06 | 2024-01-01 | Univ Texas | Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof |
WO2017214170A2 (en) | 2016-06-06 | 2017-12-14 | City Of Hope | Baff-r antibodies and uses thereof |
JP7076711B2 (en) | 2016-07-02 | 2022-05-30 | プロセナ バイオサイエンシーズ リミテッド | Anti-transthyretin antibody |
EP3478716A2 (en) | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
JP7016470B2 (en) | 2016-07-02 | 2022-02-07 | プロセナ バイオサイエンシーズ リミテッド | Anti-transthyretin antibody |
BR112019000166A2 (en) | 2016-07-06 | 2019-10-01 | Celgene Corp | antibodies with low immunogenicity and their uses |
KR20190039937A (en) | 2016-07-08 | 2019-04-16 | 스태튼 바이오테크놀로지 비.브이. | Anti-ApoC3 antibodies and methods of use thereof |
EP3481869A4 (en) | 2016-07-11 | 2020-02-26 | Corvus Pharmaceuticals, Inc. | Anti-cd73 antibodies |
PE20190227A1 (en) | 2016-07-12 | 2019-02-13 | H Lundbeck As | SPECIFIC ANTIBODIES FOR HYPERPHOSPHORILATED TAU AND THEIR METHODS OF USE |
ES2960835T3 (en) | 2016-07-12 | 2024-03-06 | Kite Pharma Inc | Antigen binding molecules and methods of use thereof |
CA3030926A1 (en) | 2016-07-19 | 2018-01-25 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-cd47 combination therapy |
EP3487883B1 (en) | 2016-07-20 | 2023-01-04 | Stcube, Inc. | Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1 |
CN109562153A (en) | 2016-08-07 | 2019-04-02 | 诺华股份有限公司 | The immunization method that mRNA is mediated |
AU2017308734A1 (en) | 2016-08-12 | 2019-02-14 | Janssen Biotech, Inc. | Fc engineered anti-TNFR superfamily member antibodies having enhanced agonistic activity and methods of using them |
US10669344B2 (en) | 2016-08-12 | 2020-06-02 | Janssen Biotech, Inc. | Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions |
AU2017331739A1 (en) | 2016-09-23 | 2019-03-07 | Csl Limited | Coagulation factor binding proteins and uses thereof |
EP3518972A4 (en) | 2016-09-28 | 2020-07-22 | Kite Pharma, Inc. | Antigen binding molecules and methods of use thereof |
TWI773694B (en) | 2016-10-11 | 2022-08-11 | 美商艾吉納斯公司 | Anti-lag-3 antibodies and methods of use thereof |
CA3041717A1 (en) | 2016-11-09 | 2018-05-17 | North Carolina State University | Treatment of allergic diseases with chimeric protein |
MA46836A (en) | 2016-11-15 | 2019-09-25 | H Lundbeck As | AGENTS, USES AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHY |
JOP20170192A1 (en) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | Cyclic dinucleotide |
JP6992068B2 (en) | 2016-12-07 | 2022-02-03 | アジェナス インコーポレイテッド | Anti-CTLA-4 antibodies and how to use them |
PE20190921A1 (en) | 2016-12-07 | 2019-06-26 | Agenus Inc | ANTIBODIES AND METHODS OF THEIR USE |
BR112018016717A2 (en) | 2016-12-16 | 2018-12-26 | H Lundbeck As | agents, uses and methods |
US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
BR112018067721A2 (en) | 2017-01-04 | 2019-01-08 | H Lundbeck As | hyperphosphorylated tau specific antibodies for the treatment of eye diseases |
EP3583129B1 (en) | 2017-02-14 | 2021-11-03 | Kite Pharma, Inc. | Cd70 binding molecules and methods of use thereof |
WO2018169922A2 (en) | 2017-03-13 | 2018-09-20 | Kite Pharma, Inc. | Chimeric antigen receptors for melanoma and uses thereof |
WO2018166495A1 (en) | 2017-03-15 | 2018-09-20 | Tsinghua University | Novel anti-trkb antibodies |
EA201992278A1 (en) | 2017-03-27 | 2020-03-03 | Селджин Корпорейшн | METHODS AND COMPOSITIONS FOR REDUCING IMMUNOGENOUS |
SG11201908280SA (en) | 2017-03-30 | 2019-10-30 | Univ Queensland | "chimeric molecules and uses thereof" |
WO2018191502A2 (en) | 2017-04-13 | 2018-10-18 | Agenus Inc. | Anti-cd137 antibodies and methods of use thereof |
EP3610010A4 (en) | 2017-04-14 | 2021-02-24 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
KR20190141659A (en) | 2017-04-21 | 2019-12-24 | 스태튼 바이오테크놀로지 비.브이. | Anti-APOC3 Antibodies and Methods of Use thereof |
JOP20180042A1 (en) | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | Humanized Antigen-Binding Domains and Methods of Use |
SI3618863T1 (en) | 2017-05-01 | 2023-12-29 | Agenus Inc. | Anti-tigit antibodies and methods of use thereof |
MX2019013045A (en) | 2017-05-02 | 2020-02-12 | Prothena Biosciences Ltd | Antibodies recognizing tau. |
JOP20190256A1 (en) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | Newcastle disease viruses and uses thereof |
CA3065516A1 (en) | 2017-06-05 | 2018-12-13 | Janssen Biotech, Inc. | Antibodies that specifically bind pd-1 and methods of use |
US11892457B2 (en) | 2017-07-12 | 2024-02-06 | The Johns Hopkins University | Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis |
US10894833B2 (en) | 2017-07-20 | 2021-01-19 | H. Lundbeck A/S | Agents, uses and methods for treatment |
WO2020159504A1 (en) | 2019-01-30 | 2020-08-06 | Nomocan Pharmaceuticals Llc | Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer |
JP2020528936A (en) | 2017-07-27 | 2020-10-01 | ノモキャン ファーマシューティカルズ エルエルシー | Antibodies to M (H) DM2 / 4 and their use in the diagnosis and treatment of cancer |
JP7437301B2 (en) | 2017-08-25 | 2024-02-22 | ファイヴ プライム セラピューティクス インク | B7-H4 antibody and its usage |
GB2581619A (en) | 2017-09-15 | 2020-08-26 | Univ California | Inhibition of aminoacylase 3 (AA3) in the treatment of cancer |
AU2018334279A1 (en) | 2017-09-15 | 2020-04-02 | Kite Pharma, Inc. | Methods and systems for performing a patient-specific immunotherapy procedure with chain-of-custody and chain-of-identity biological sample tracking |
US11596694B2 (en) | 2017-09-20 | 2023-03-07 | Mersana Therapeutics, Inc. | Compositions and methods for predicting response to NaPi2b-targeted therapy |
US10844371B2 (en) | 2017-09-22 | 2020-11-24 | Kite Pharma, Inc. | Antigen binding molecules and methods of use thereof |
WO2019064053A1 (en) | 2017-09-28 | 2019-04-04 | Prothena Biosciences Limited | Dosing regimes for treatment of synucleinopathies |
EP3700932A1 (en) | 2017-10-27 | 2020-09-02 | Kite Pharma, Inc. | T cell receptor antigen binding molecules and methods of use thereof |
WO2019087115A1 (en) | 2017-10-31 | 2019-05-09 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
WO2019099707A1 (en) | 2017-11-16 | 2019-05-23 | Kite Pharma, Inc | Modified chimeric antigen receptors and methods of use |
US10772970B2 (en) | 2017-12-01 | 2020-09-15 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
MX2020005640A (en) | 2017-12-01 | 2020-08-20 | Seattle Genetics Inc | Humanized anti-liv1 antibodies for the treatment of breast cancer. |
MX2020005463A (en) | 2017-12-01 | 2020-09-07 | Seattle Genetics Inc | Cd47 antibodies and uses thereof for treating cancer. |
US20190225689A1 (en) | 2018-01-22 | 2019-07-25 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-pd-1 antibodies |
EP4253959A3 (en) | 2018-02-14 | 2023-11-22 | Kite Pharma, Inc. | Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule |
CA3091174A1 (en) | 2018-02-21 | 2019-08-29 | Five Prime Therapeutics, Inc. | B7-h4 antibody formulations |
EP3755719A1 (en) | 2018-02-21 | 2020-12-30 | Five Prime Therapeutics, Inc. | B7-h4 antibody dosing regimens |
EP3756009B1 (en) | 2018-02-23 | 2023-09-06 | Meso Scale Technologies, LLC | Methods of screening antigen-binding molecules by normalizing for the concentration of antigen-binding molecule |
SG11202008105RA (en) | 2018-03-02 | 2020-09-29 | Five Prime Therapeutics Inc | B7-h4 antibodies and methods of use thereof |
CN112088169A (en) | 2018-03-12 | 2020-12-15 | 纪念斯隆凯特琳癌症中心 | Bispecific binding agents and uses thereof |
JOP20200302A1 (en) | 2018-05-24 | 2020-11-23 | Janssen Biotech Inc | Anti-cd3 antibodies and uses thereof |
EA202092839A1 (en) | 2018-05-24 | 2021-02-12 | Янссен Байотек, Инк. | PSMA LINKING AGENTS AND THEIR APPLICATIONS |
EP3802607A2 (en) | 2018-05-24 | 2021-04-14 | Janssen Biotech, Inc. | Monospecific and multispecific anti-tmeff2 antibodies and there uses |
EP3814376A4 (en) | 2018-06-26 | 2022-07-06 | Mor Research Applications Ltd. | Transthyretin antibodies and uses thereof |
EP3817770A2 (en) | 2018-07-02 | 2021-05-12 | Amgen Inc. | Anti-steap1 antigen-binding protein |
EP3840838A2 (en) | 2018-07-24 | 2021-06-30 | MedImmune, LLC | Antibody directed against s.aureus clumping factor a (clfa) |
TW202035452A (en) | 2018-08-17 | 2020-10-01 | 美商梅爾莎納醫療公司 | Napi2b-targeted polymer antibody-drug conjugates and methods of use thereof |
AU2019352017A1 (en) | 2018-10-03 | 2021-05-06 | Staten Biotechnology B.V. | Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof |
AU2019359207A1 (en) | 2018-10-09 | 2021-05-20 | Humabs Biomed Sa | Antibodies directed against Staphylococcus aureus leukotoxins |
EP3864041A2 (en) | 2018-10-09 | 2021-08-18 | Medimmune, LLC | Combinations of anti-staphylococcus aureus antibodies |
CA3114955A1 (en) | 2018-10-15 | 2020-04-23 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
CR20210272A (en) | 2018-11-26 | 2021-07-14 | Forty Seven Inc | HUMANIZED http://aplpatentes:48080/IpasWeb/PatentEdit/ViewPatentEdit.do#ANTIBODIES AGAINST C-KIT |
EP3886869A4 (en) | 2018-11-28 | 2022-07-06 | Forty Seven, Inc. | Genetically modified hspcs resistant to ablation regime |
MX2021006968A (en) | 2018-12-12 | 2021-10-13 | Kite Pharma Inc | Chimeric antigen receptors and car-t cells and methods of use. |
TW202039573A (en) | 2018-12-21 | 2020-11-01 | 美商亞維代堤生物科學公司 | Anti-transferrin receptor antibodies and uses thereof |
RU2711871C1 (en) * | 2018-12-25 | 2020-01-23 | Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) | Monoclonal antibodies which specifically bind to the beta-chain region of the trbv-9 family of the human t-cell receptor, and methods for use thereof |
TW202043256A (en) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | Prostate neoantigens and their uses |
CN113348178A (en) | 2019-01-28 | 2021-09-03 | 枫叶生物技术有限公司 | PSMP antagonists for the treatment of fibrotic diseases of the lung, kidney or liver |
CN113710271A (en) | 2019-02-05 | 2021-11-26 | 西根股份有限公司 | anti-CD 228 antibodies and antibody-drug conjugates |
TW202045547A (en) | 2019-03-01 | 2020-12-16 | 美商艾洛基因醫療公司 | Dll3 targeting chimeric antigen receptors and binding agents |
SG11202108414UA (en) | 2019-03-03 | 2021-08-30 | Prothena Biosciences Ltd | Antibodies recognizing tau |
WO2020185986A1 (en) | 2019-03-13 | 2020-09-17 | Medimmune, Llc | Decreasing staphylococcus aureus infections in colonized patients |
WO2020210650A1 (en) | 2019-04-12 | 2020-10-15 | Medimmune, Llc | Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections |
JP2022529985A (en) | 2019-04-19 | 2022-06-27 | ヤンセン バイオテツク,インコーポレーテツド | How to treat prostate cancer with anti-PSMA / CD3 antibody |
KR20220002888A (en) | 2019-04-19 | 2022-01-07 | 알로젠 테라퓨틱스 인코포레이티드 | Antibodies to 4G7-derived chimeric antigen receptors |
KR20220003055A (en) | 2019-04-30 | 2022-01-07 | 기가젠, 인코포레이티드 | Recombinant polyclonal proteins and methods of use thereof |
EP3969043A1 (en) | 2019-05-15 | 2022-03-23 | Neotx Therapeutics Ltd. | Cancer treatment |
WO2020237227A1 (en) | 2019-05-22 | 2020-11-26 | Massachusetts Institute Of Technology | Circular rna compositions and methods |
US20220259329A1 (en) | 2019-06-07 | 2022-08-18 | Amgen Inc. | Bispecific binding constructs |
BR112021025029A2 (en) | 2019-06-13 | 2022-01-25 | Allogene Therapeutics Inc | Anti-talen antibodies and their uses |
WO2020257823A2 (en) | 2019-06-21 | 2020-12-24 | Kite Pharma, Inc. | TGF-β RECEPTORS AND METHODS OF USE |
TW202116810A (en) | 2019-07-22 | 2021-05-01 | 美商西雅圖遺傳學股份有限公司 | Humanized anti-liv1 antibodies for the treatment of cancer |
WO2021019389A1 (en) | 2019-07-26 | 2021-02-04 | Janssen Biotech, Inc. | Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses |
WO2021042019A1 (en) | 2019-08-30 | 2021-03-04 | Agenus Inc. | Anti-cd96 antibodies and methods of use thereof |
US20220411511A1 (en) | 2019-09-26 | 2022-12-29 | Stcube & Co. | Antibodies specific to glycosylated ctla-4 and methods of use thereof |
BR112022005114A2 (en) | 2019-10-04 | 2022-06-21 | Seagen Inc | Antibody, pharmaceutical composition, methods for treating cancer and for producing an antibody-drug conjugate and an antibody, nucleic acid, vector, host cell, and, antibody-drug conjugate |
US20220356248A1 (en) | 2019-10-09 | 2022-11-10 | Stcube & Co | Antibodies specific to glycosylated lag3 and methods of use thereof |
EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
US20220396628A1 (en) | 2019-10-23 | 2022-12-15 | Kite Pharma, Inc. | Anti-idiotypic antigen binding molecules and methods of use thereof |
AU2020385683A1 (en) | 2019-11-18 | 2022-06-30 | Janssen Biotech, Inc. | Vaccines based on mutant CALR and JAK2 and their uses |
TW202138388A (en) | 2019-12-30 | 2021-10-16 | 美商西根公司 | Methods of treating cancer with nonfucosylated anti-cd70 antibodies |
US20210253685A1 (en) | 2020-01-08 | 2021-08-19 | Regeneron Pharmaceuticals, Inc. | Treatment of fibrodysplasia ossificans progressiva |
US20230138520A1 (en) * | 2020-01-16 | 2023-05-04 | Caerus Therapeutics, Inc. | Humanized antibodies specific for myeloma and ovarian cancer cells |
US20230078601A1 (en) | 2020-01-31 | 2023-03-16 | The Cleveland Clinic Foundation | Anti-mullerian hormone receptor 2 antibodies and methods of use |
TW202140012A (en) | 2020-02-12 | 2021-11-01 | 比利時商健生藥品公司 | Fgfr tyrosine kinase inhibitors and anti-pd1 agents for the treatment of urothelial carcinoma |
TW202144388A (en) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | Neoantigens expressed in ovarian cancer and their uses |
TW202144389A (en) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | Neoantigens expressed in multiple myeloma and their uses |
WO2021167908A1 (en) | 2020-02-17 | 2021-08-26 | Board Of Regents, The University Of Texas System | Methods for expansion of tumor infiltrating lymphocytes and use thereof |
BR112022016368A2 (en) | 2020-02-18 | 2023-01-10 | Alector Llc | PILRA ANTIBODIES AND THEIR METHODS OF USE |
EP4118112A1 (en) | 2020-03-10 | 2023-01-18 | Massachusetts Institute of Technology | Compositions and methods for immunotherapy of npm1c-positive cancer |
WO2021183675A2 (en) | 2020-03-10 | 2021-09-16 | Massachusetts Institute Of Technology | Methods for generating engineered memory-like nk cells and compositions thereof |
EP4233894A3 (en) | 2020-03-13 | 2023-09-27 | Janssen Biotech, Inc. | Materials and methods for binding siglec-3/cd33 |
WO2021186398A1 (en) | 2020-03-19 | 2021-09-23 | Medimmune Limited | Anti-klebsiella pneumoniae antibodies and uses thereof |
US11555190B2 (en) | 2020-03-19 | 2023-01-17 | Avidity Biosciences, Inc. | Compositions and methods of treating Facioscapulohumeral muscular dystrophy |
AU2021237738A1 (en) | 2020-03-20 | 2022-11-10 | Orna Therapeutics, Inc. | Circular RNA compositions and methods |
CA3176257A1 (en) | 2020-03-26 | 2021-09-30 | Seagen Inc. | Methods of treating multiple myeloma |
EP4126066A4 (en) | 2020-03-27 | 2024-04-24 | Avidity Biosciences Inc | Compositions and methods of treating muscle dystrophy |
EP4136115A2 (en) | 2020-04-17 | 2023-02-22 | New York University | Therapeutic musk antibodies |
MX2022014422A (en) | 2020-05-17 | 2022-12-07 | Astrazeneca Uk Ltd | Sars-cov-2 antibodies and methods of selecting and using the same. |
BR112022023554A2 (en) | 2020-05-19 | 2023-04-11 | Orna Therapeutics Inc | CIRCULAR RNA COMPOSITIONS AND METHODS |
CN116249714A (en) | 2020-05-27 | 2023-06-09 | 詹森生物科技公司 | Protein comprising CD3 antigen binding domain and uses thereof |
MX2022015157A (en) | 2020-06-02 | 2023-01-16 | Arcus Biosciences Inc | Antibodies to tigit. |
AU2021283933A1 (en) | 2020-06-04 | 2023-01-05 | Amgen Inc. | Bispecific binding constructs |
CA3177152A1 (en) | 2020-06-12 | 2021-12-16 | David Scott Johnson | Recombinant polyclonal proteins targeting covid-19 and methods of use thereof |
US20230279078A1 (en) | 2020-07-20 | 2023-09-07 | Astrazeneca Uk Limited | Sars-cov-2 proteins, anti-sars-cov-2 antibodies, and methods of using the same |
TW202221028A (en) | 2020-07-29 | 2022-06-01 | 美商健生生物科技公司 | Proteins comprising hla-g antigen binding domains and their uses |
WO2022031834A1 (en) | 2020-08-05 | 2022-02-10 | Gigagen, Inc. | Recombinant polyclonal proteins targeting zika and methods of use thereof |
IL300528A (en) | 2020-08-07 | 2023-04-01 | Fortis Therapeutics Inc | Immunoconjugates targeting cd46 and methods of use thereof |
US20220041694A1 (en) | 2020-08-10 | 2022-02-10 | Astrazeneca Uk Limited | Sars-cov-2 antibodies for treatment and prevention of covid-19 |
CA3191161A1 (en) | 2020-08-14 | 2022-02-17 | Kite Pharma, Inc | Improving immune cell function |
KR102607909B1 (en) | 2020-08-19 | 2023-12-01 | 젠코어 인코포레이티드 | Anti-CD28 composition |
EP4201961A1 (en) | 2020-08-21 | 2023-06-28 | Shanghai Genbase Biotechnology Co., Ltd. | Antibody specifically bound to glycosylated ceacam5 |
EP4204545A2 (en) | 2020-08-25 | 2023-07-05 | Kite Pharma, Inc. | T cells with improved functionality |
IL300930A (en) | 2020-08-27 | 2023-04-01 | Enosi Therapeutics Corp | Methods and compositions to treat autoimmune diseases and cancer |
WO2022067348A1 (en) | 2020-09-28 | 2022-03-31 | Seagen Inc. | Humanized anti-liv1 antibodies for the treatment of cancer |
UY39467A (en) | 2020-10-13 | 2022-04-29 | Janssen Biotech Inc | BIOENGINEERED T-CELL-MEDIATED IMMUNITY, MATERIALS, AND OTHER METHODS TO MODULATE DIFFERENTIATION GROUP IV AND/OR VIII |
IL303205A (en) | 2020-12-03 | 2023-07-01 | Amgen Inc | Immunoglobuline constructs with multiple binding domains |
EP4263590A1 (en) | 2020-12-21 | 2023-10-25 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
EP4267623A1 (en) | 2020-12-24 | 2023-11-01 | Kite Pharma, Inc. | Prostate cancer chimeric antigen receptors |
US20240059789A1 (en) | 2021-01-28 | 2024-02-22 | Janssen Biotech, Inc. | Psma binding proteins and uses thereof |
KR20230135593A (en) | 2021-01-28 | 2023-09-25 | 알로젠 테라퓨틱스 인코포레이티드 | Method for transducing immune cells |
EP4284918A1 (en) | 2021-01-29 | 2023-12-06 | Allogene Therapeutics, Inc. | Knockdown or knockout of one or more of tap2, nlrc5, beta2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products |
AU2022223409A1 (en) | 2021-02-19 | 2023-09-21 | Theripion, Inc. | Dnase fusion polypeptides and related compositions and methods |
US20220281950A1 (en) | 2021-03-04 | 2022-09-08 | Allogene Therapeutics, Inc. | Fasl expression and fasr gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell death |
KR20230155521A (en) | 2021-03-11 | 2023-11-10 | 카이트 파마 인코포레이티드 | Improved immune cell function |
WO2022201052A1 (en) | 2021-03-24 | 2022-09-29 | Janssen Biotech, Inc. | Antibody targeting cd22 and cd79b |
EP4323400A1 (en) | 2021-04-16 | 2024-02-21 | Kite Pharma, Inc. | Taci/bcma dual binding molecules |
EP4347638A2 (en) | 2021-05-24 | 2024-04-10 | Kite Pharma, Inc. | Nkg2d-based chimeric antgen receptor |
TW202314247A (en) | 2021-05-25 | 2023-04-01 | 美商思進公司 | Methods of quantifying anti-cd40 antibodies |
CN113393899A (en) * | 2021-05-26 | 2021-09-14 | 江苏普瑞康生物医药科技有限公司 | Method and device for antibody humanization based on dynamic programming |
CN117730100A (en) | 2021-06-08 | 2024-03-19 | 凯德药业股份有限公司 | GPC3 binding molecules |
TW202317767A (en) | 2021-06-10 | 2023-05-01 | 美商歐納醫療公司 | Circular rna compositions and methods |
EP4355776A1 (en) | 2021-06-14 | 2024-04-24 | Argenx BV | Anti-il-9 antibodies and methods of use thereof |
KR20240021826A (en) | 2021-06-15 | 2024-02-19 | 알로젠 테라퓨틱스 인코포레이티드 | Selective targeting of host CD70+ alloreactive cells to prolong allogeneic CAR T cell persistence |
WO2022263632A1 (en) | 2021-06-18 | 2022-12-22 | Alligator Bioscience Ab | Novel combination therapies and uses thereof |
KR20240025597A (en) | 2021-06-29 | 2024-02-27 | 씨젠 인크. | Methods of treating cancer with a combination of afucosylated anti-CD70 antibody and CD47 antagonist |
TW202315638A (en) | 2021-07-01 | 2023-04-16 | 美商得納利醫療公司 | Oligonucleotide conjugates targeted to the transferrin receptor |
CA3226269A1 (en) | 2021-07-14 | 2023-01-19 | Lycia Therapeutics, Inc. | Asgpr cell surface receptor binding compounds and conjugates |
AU2022310346A1 (en) | 2021-07-14 | 2024-01-25 | Lycia Therapeutics, Inc. | M6pr cell surface receptor binding compounds and conjugates |
WO2023009989A1 (en) | 2021-07-26 | 2023-02-02 | Kite Pharma, Inc. | Split chimeric antigen receptors and methods of use |
AU2022330106A1 (en) | 2021-08-16 | 2024-03-21 | Hemogenyx Pharmaceuticals Llc | Anti-flt3 antibodies, cars, car t cells and methods of use |
WO2023023489A2 (en) | 2021-08-17 | 2023-02-23 | Hemogenyx Pharmaceuticals Llc | Bispecific anti-flt3/cd3 antibodies and methods of use |
IL310662A (en) | 2021-08-23 | 2024-04-01 | Immunitas Therapeutics Inc | Anti-cd161 antibodies and uses thereof |
CN117881784A (en) | 2021-08-31 | 2024-04-12 | 大正制药株式会社 | Anti-growth hormone antibodies |
WO2023043953A1 (en) | 2021-09-16 | 2023-03-23 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
TW202327650A (en) | 2021-09-23 | 2023-07-16 | 美商思進公司 | Methods of treating multiple myeloma |
WO2023046322A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceutica Nv | Proteins comprising cd20 binding domains, and uses thereof |
AU2022353839A1 (en) | 2021-09-30 | 2024-05-02 | Orna Therapeutics, Inc. | Lipid nanoparticle compositions for delivering circular polynucleotides |
CA3232806A1 (en) | 2021-09-30 | 2023-04-06 | Seagen Inc. | B7-h4 antibody-drug conjugates for the treatment of cancer |
TW202325736A (en) | 2021-10-18 | 2023-07-01 | 美商凱特製藥公司 | Signaling domains for chimeric antigen receptors |
WO2023066336A1 (en) * | 2021-10-21 | 2023-04-27 | 江苏先声药业有限公司 | Anti-muc17 nanobody and use thereof |
WO2023072159A1 (en) | 2021-10-27 | 2023-05-04 | Virtuoso Binco, Inc. | Multispecific antibodies for treating cd47-associated diseases |
TW202342095A (en) | 2021-11-05 | 2023-11-01 | 英商阿斯特捷利康英國股份有限公司 | Composition for treatment and prevention of covid-19 |
CA3236235A1 (en) | 2021-11-08 | 2023-05-11 | Orna Therapeutics, Inc. | Lipid nanoparticle compositions for delivering circular polynucleotides |
WO2023131219A1 (en) | 2022-01-06 | 2023-07-13 | Virtuoso Binco, Inc. | Conjugates, compositions and methods of use |
WO2023152581A1 (en) | 2022-02-09 | 2023-08-17 | Janssen Biotech, Inc. | Method of treating cancer with psmaxcd3 antibody |
WO2023192895A1 (en) | 2022-03-29 | 2023-10-05 | Allogene Therapeutics Inc. | Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals |
WO2023209177A1 (en) | 2022-04-29 | 2023-11-02 | Astrazeneca Uk Limited | Sars-cov-2 antibodies and methods of using the same |
WO2023218099A1 (en) | 2022-05-13 | 2023-11-16 | argenx BV | In utero treatment of a fetus having genetic disease/neuromuscular disease |
WO2023247050A1 (en) | 2022-06-23 | 2023-12-28 | Alligator Bioscience Ab | Combination therapies |
US20240052049A1 (en) | 2022-06-24 | 2024-02-15 | Orna Therapeutics, Inc. | Circular rna encoding chimeric antigen receptors targeting bcma |
GB202210965D0 (en) | 2022-07-27 | 2022-09-07 | Alligator Bioscience Ab | Novel dosages |
GB202210957D0 (en) | 2022-07-27 | 2022-09-07 | Alligator Bioscience Ab | Novel dosages |
WO2024026471A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
TW202405020A (en) | 2022-07-29 | 2024-02-01 | 美商阿列克特有限責任公司 | Transferrin receptor antigen-binding domains and uses therefor |
WO2024026445A1 (en) | 2022-07-29 | 2024-02-01 | Allogene Therapeutics Inc. | Engineered cells with reduced gene expression to mitigate immune cell recognition |
US20240091261A1 (en) | 2022-08-26 | 2024-03-21 | Kite Pharma, Inc. | Immune cell function |
WO2024051806A1 (en) * | 2022-09-09 | 2024-03-14 | 南京金斯瑞生物科技有限公司 | Method for designing humanized antibody sequence |
US20240101710A1 (en) | 2022-09-19 | 2024-03-28 | Allogene Therapeutics, Inc. | B-cell maturation antigen (bcma) anti-idiotypic antibodies |
GB202215115D0 (en) | 2022-10-13 | 2022-11-30 | Univ Nottingham | VEGF antibodies |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6479284B1 (en) * | 1998-03-13 | 2002-11-12 | Dana-Farber Cancer Institute, Inc. | Humanized antibody and uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
LU91067I2 (en) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab and its variants and immunochemical derivatives including immotoxins |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
FR2724393A1 (en) * | 1994-09-12 | 1996-03-15 | Inst Nat Sante Rech Med | OBTAINING A HUMANIZED RECOMBINANT MONOCLONAL ANTIBODY FROM A MURIN MONOCLONAL ANTIBODY, ITS PRODUCTION IN INSECT CELLS, AND USES THEREOF |
MXPA05000511A (en) * | 2001-07-12 | 2005-09-30 | Jefferson Foote | Super humanized antibodies. |
-
2002
- 2002-07-12 MX MXPA05000511A patent/MXPA05000511A/en active IP Right Grant
- 2002-07-12 AU AU2002368077A patent/AU2002368077B2/en not_active Expired
- 2002-07-12 CN CN02829598.6A patent/CN1671416B/en not_active Expired - Lifetime
- 2002-07-12 WO PCT/US2002/022011 patent/WO2004006955A1/en active Search and Examination
- 2002-07-12 US US10/194,975 patent/US6881557B2/en not_active Expired - Lifetime
- 2002-07-12 JP JP2004521391A patent/JP2005538706A/en not_active Withdrawn
- 2002-07-12 EP EP02752269A patent/EP1539233B1/en not_active Revoked
- 2002-07-12 EP EP10185475A patent/EP2298809A3/en not_active Withdrawn
- 2002-07-12 IL IL16624402A patent/IL166244A0/en unknown
- 2002-07-12 CA CA2491864A patent/CA2491864C/en not_active Expired - Lifetime
-
2005
- 2005-02-08 US US11/054,669 patent/US7732578B2/en not_active Expired - Lifetime
-
2006
- 2006-05-10 US US11/432,734 patent/US7709226B2/en not_active Expired - Lifetime
-
2010
- 2010-03-29 US US12/749,257 patent/US20110137014A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6479284B1 (en) * | 1998-03-13 | 2002-11-12 | Dana-Farber Cancer Institute, Inc. | Humanized antibody and uses thereof |
Non-Patent Citations (5)
Title |
---|
MHASHILKAR A.M. ET AL.: "Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies", HUMAN GENE THERAPY, vol. 10, 10 June 1999 (1999-06-10), pages 1453 - 1467, XP002928231 * |
MOREA V. ET AL.: "Antibody modeling: Implications for engineering and design", METHODS, vol. 20, no. 3, 2000, pages 267 - 279, XP004466884 * |
ROSOK M.J. ET AL.: "A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 37, 13 September 1996 (1996-09-13), pages 22611 - 22618, XP002920742 * |
See also references of EP1539233A4 * |
WU H. ET AL.: "Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues", JOURNAL OF MOLECULAR BIOLOGY, vol. 294, 1999, pages 151 - 162, XP002166821 * |
Cited By (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7575893B2 (en) | 2003-01-23 | 2009-08-18 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
US7981843B2 (en) | 2004-01-20 | 2011-07-19 | Kalobios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
EP2404935A1 (en) | 2004-03-30 | 2012-01-11 | Glaxo Group Limited | Immunoglobulin binding HOSM |
WO2005112564A3 (en) * | 2004-04-15 | 2007-01-18 | Us Gov Health & Human Serv | Germline and sequence variants of humanized antibodies and methods of making and using them |
WO2005112564A2 (en) * | 2004-04-15 | 2005-12-01 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Germline and sequence variants of humanized antibodies and methods of making and using them |
US10919983B2 (en) | 2004-11-16 | 2021-02-16 | Humanigen, Inc. | Immunoglobulin variable region cassette exchange |
EP3540062A1 (en) * | 2004-11-16 | 2019-09-18 | Humanigen, Inc. | Immunoglobulin variable region cassette exchange |
WO2006055778A2 (en) | 2004-11-16 | 2006-05-26 | Kalobios, Inc. | Immunoglobulin variable region cassette exchange |
EP2343380A1 (en) * | 2004-11-16 | 2011-07-13 | Kalobios Inc. | Immunoglobulin variable region cassette exchange |
EP1824987A4 (en) * | 2004-11-16 | 2008-03-19 | Kalobios Inc | Immunoglobulin variable region cassette exchange |
EP1824987A2 (en) * | 2004-11-16 | 2007-08-29 | Kalobios Inc. | Immunoglobulin variable region cassette exchange |
US7855276B2 (en) | 2004-12-30 | 2010-12-21 | The United States Of America As Represented By The Department Of Health And Human Services | Framework residue substituted humanized COL-1 antibodies and their use |
US8828717B2 (en) | 2004-12-30 | 2014-09-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Framework residue substituted humanized COL-1 antibodies and their use |
JP2008531060A (en) * | 2005-03-04 | 2008-08-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | A method for humanizing immunoglobulin variable regions via rational modification of complementarity determining residues |
US7678371B2 (en) | 2005-03-04 | 2010-03-16 | Biogen Idec Ma Inc. | Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues |
US8349324B2 (en) | 2005-03-04 | 2013-01-08 | Biogen Idec Ma Inc. | Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues |
WO2006096653A2 (en) * | 2005-03-04 | 2006-09-14 | Biogen Idec Ma Inc. | Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues |
WO2006096653A3 (en) * | 2005-03-04 | 2007-07-12 | Biogen Idec Inc | Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues |
AU2006220709B2 (en) * | 2005-03-04 | 2012-09-06 | Biogen Ma Inc. | Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues |
JP2009502171A (en) * | 2005-07-25 | 2009-01-29 | トゥルビオン・ファーマシューティカルズ・インコーポレーテッド | Reduction of B cells using CD37-specific and CD20-specific binding molecules |
US10307481B2 (en) | 2005-07-25 | 2019-06-04 | Aptevo Research And Development Llc | CD37 immunotherapeutics and uses thereof |
JP2012165760A (en) * | 2005-07-25 | 2012-09-06 | Emergent Product Development Seattle Llc | B-cell reduction using cd37-specific and cd20-specific binding molecules |
US10143748B2 (en) | 2005-07-25 | 2018-12-04 | Aptevo Research And Development Llc | B-cell reduction using CD37-specific and CD20-specific binding molecules |
JP2014196350A (en) * | 2005-07-25 | 2014-10-16 | エマージェント・プロダクト・ディベロップメント・シアトル・エルエルシー | B-cell reduction using cd37-specific and cd20-specific binding molecules |
EP2228391A2 (en) | 2005-12-16 | 2010-09-15 | Glaxo Group Limited | Immunoglobulins directed against Nogo |
WO2007068750A2 (en) | 2005-12-16 | 2007-06-21 | Glaxo Group Limited | Immunoglobulins directed against nogo |
EP2423229A1 (en) | 2006-03-27 | 2012-02-29 | Medimmune Limited | Binding member for GM-CSF receptor |
EP2423230A1 (en) | 2006-03-27 | 2012-02-29 | Medimmune Limited | Binding member for GM-CSF receptor |
WO2007137984A2 (en) | 2006-05-25 | 2007-12-06 | Glaxo Group Limited | Modified humanised anti-interleukin-18 antibodies |
WO2008017126A1 (en) | 2006-08-11 | 2008-02-14 | Csl Limited | Treatment of pulmonary disease conditions |
EP2526959A1 (en) | 2006-08-11 | 2012-11-28 | CSL Limited | Treatment of pulmonary disease conditions |
EP2530090A2 (en) | 2006-10-19 | 2012-12-05 | CSL Limited | Anti-IL-13R alpha 1 antibodies and their uses thereof |
EP2628751A2 (en) | 2006-11-30 | 2013-08-21 | AstraZeneca AB | Binding members for interleukin-6 and use thereof |
EP2620452A1 (en) | 2007-02-15 | 2013-07-31 | Medimmune Limited | Binding members for IGE molecules |
US10494432B2 (en) | 2007-07-16 | 2019-12-03 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
US11866496B2 (en) | 2007-07-16 | 2024-01-09 | Genentech, Inc. | Humanized anti-CD79B antibodies and immunoconjugates and methods of use |
US10981987B2 (en) | 2007-07-16 | 2021-04-20 | Genentech, Inc. | Humanized anti-CD79b antibodies and immunoconjugates and methods of use |
JP2010533495A (en) * | 2007-07-16 | 2010-10-28 | ジェネンテック, インコーポレイテッド | Humanized CD79b antibodies and immunoconjugates and their use |
USRE48558E1 (en) | 2007-07-16 | 2021-05-18 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
US9845355B2 (en) | 2007-07-16 | 2017-12-19 | Genentech, Inc. | Humanized anti-CD79b antibodies and immunoconjugates and methods of use |
JP2014207919A (en) * | 2007-07-16 | 2014-11-06 | ジェネンテック, インコーポレイテッド | HUMANIZED ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES, AND METHODS OF USING THE SAME |
EP2050765A1 (en) * | 2007-10-19 | 2009-04-22 | Centocor, Inc. | Methods for use in human-adapting monoclonal antibodies |
US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
US10544218B2 (en) | 2008-01-31 | 2020-01-28 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
KR20160116056A (en) | 2008-08-14 | 2016-10-06 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | Anti-il-12/il-23 antibodies |
US8741604B2 (en) | 2008-11-07 | 2014-06-03 | Medimmune Limited | Nucleic acid molecule encoding a specific IL-1R1 antibody |
US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
US9200074B2 (en) | 2008-11-07 | 2015-12-01 | Medimmune Limited | Antibodies to IL-1 R1 and methods of making them |
WO2010070094A1 (en) | 2008-12-19 | 2010-06-24 | Glaxo Group Limited | Myostatin binding proteins |
WO2011076883A1 (en) | 2009-12-23 | 2011-06-30 | 4-Antibody Ag | Binding members for human cytomegalovirus |
WO2011094259A2 (en) | 2010-01-28 | 2011-08-04 | Glaxo Group Limited | Cd127 binding proteins |
US11026407B2 (en) | 2010-02-08 | 2021-06-08 | Regeneran Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US10412940B2 (en) | 2010-02-08 | 2019-09-17 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US10143186B2 (en) | 2010-02-08 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
US10167344B2 (en) | 2010-02-08 | 2019-01-01 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US9969814B2 (en) | 2010-02-08 | 2018-05-15 | Regeneron Pharmaceuticals, Inc. | Methods for making fully human bispecific antibodies using a common light chain |
US10986820B2 (en) | 2010-02-08 | 2021-04-27 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
EP3025729A1 (en) | 2010-03-03 | 2016-06-01 | Glaxo Group Limited | Antigen binding proteins specific for serum amyloid p component |
WO2011107480A1 (en) | 2010-03-03 | 2011-09-09 | Glaxo Group Limited | Antigen binding proteins specific for serum amyloid p component |
WO2011151432A1 (en) | 2010-06-03 | 2011-12-08 | Glaxo Group Limited | Humanised antigen binding proteins to myostatin6 |
US9605063B2 (en) | 2010-11-23 | 2017-03-28 | Glaxo Group Limited | Antigen binding proteins to Oncostatin M (OSM) |
EP3211009A1 (en) * | 2010-11-23 | 2017-08-30 | Glaxo Group Limited | Antigen binding proteins to oncostatin m (osm) |
WO2012069433A3 (en) * | 2010-11-23 | 2012-08-09 | Glaxo Group Limited | Antigen binding proteins to oncostatin m (osm) |
EA027256B1 (en) * | 2010-11-23 | 2017-07-31 | Глаксо Груп Лимитед | ANTIGEN BINDING PROTEINS WHICH BIND HUMAN ONCOSTATIN M (hOSM) |
WO2012085015A1 (en) | 2010-12-20 | 2012-06-28 | Medimmune Limited | Anti-il-18 antibodies and their uses |
US10130081B2 (en) | 2011-08-05 | 2018-11-20 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
US11357217B2 (en) | 2011-08-05 | 2022-06-14 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
US11186638B2 (en) | 2011-09-12 | 2021-11-30 | Genzyme Corporation | Anti-αβTCR antibody |
WO2013053767A1 (en) | 2011-10-10 | 2013-04-18 | Medimmune Limited | Treatment for rheumatoid arthritis |
US10196440B2 (en) | 2011-12-20 | 2019-02-05 | Janssen Biotech, Inc. | Anti-PHG-tau antibodies and their uses |
US9371376B2 (en) | 2011-12-20 | 2016-06-21 | Janssen Biotech, Inc. | Anti-PHF-tau antibodies and their uses |
US9745371B2 (en) | 2011-12-20 | 2017-08-29 | Janssen Biotech, Inc. | Anti-PHF-tau antibodies and their uses |
US10000559B2 (en) | 2011-12-20 | 2018-06-19 | Janssen Biotech, Inc. | Anti-PHF-tau antibodies and their uses |
WO2013096380A2 (en) | 2011-12-20 | 2013-06-27 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
EP3578567A1 (en) | 2011-12-20 | 2019-12-11 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
WO2014006105A1 (en) | 2012-07-05 | 2014-01-09 | Glaxo Group Limited | Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis |
EP3721942A1 (en) | 2012-10-15 | 2020-10-14 | Medimmune Limited | Antibodies to amyloid beta |
WO2014072306A1 (en) | 2012-11-08 | 2014-05-15 | F. Hoffmann-La Roche Ag | Her3 antigen binding proteins binding to the beta-hairpin of her3 |
US11807690B2 (en) | 2013-03-11 | 2023-11-07 | Genzyme Corporation | Hyperglycosylated binding polypeptides |
US11697690B2 (en) | 2014-03-19 | 2023-07-11 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
US10881085B2 (en) | 2014-03-21 | 2021-01-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
WO2015179435A1 (en) | 2014-05-19 | 2015-11-26 | Bayer Healthcare Llc | Optimized humanized monoclonal antibodies against activated protein c and uses thereof |
WO2016001140A1 (en) | 2014-06-30 | 2016-01-07 | Affiris Ag | Vaccines and monoclonal antibodies targeting truncated variants of osteopontin and uses thereof |
US10406197B2 (en) | 2014-07-10 | 2019-09-10 | Affiris Ag | Substances and methods for the use in prevention and/or treatment in Huntington's disease |
US11000510B2 (en) | 2014-09-23 | 2021-05-11 | Genentech, Inc. | Methods of using anti-CD79b immunoconjugates |
WO2016059602A2 (en) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
US10793642B2 (en) | 2014-12-11 | 2020-10-06 | Inbiomotion S.L. | Binding members for human c-MAF |
WO2016092524A1 (en) | 2014-12-11 | 2016-06-16 | Inbiomotion S.L. | Binding members for human c-maf |
US11111314B2 (en) | 2015-03-19 | 2021-09-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
WO2017158064A1 (en) | 2016-03-15 | 2017-09-21 | Astrazeneca Ab | Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta |
US10947299B2 (en) | 2016-03-23 | 2021-03-16 | Seoul National University R&Db Foundation | Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus and use for same |
EP3434690A4 (en) * | 2016-03-23 | 2020-04-01 | Seoul National University R&DB Foundation | Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus, and use for same |
WO2018170351A1 (en) | 2017-03-16 | 2018-09-20 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and uses thereof |
US11365244B2 (en) | 2017-03-16 | 2022-06-21 | Janssen Biotech, Inc. | Anti-PHF-tau antibodies and uses thereof |
US10766953B2 (en) | 2017-03-16 | 2020-09-08 | Janssen Biotech, Inc. | Anti-PHF-tau antibodies and uses thereof |
US11680110B2 (en) | 2017-07-31 | 2023-06-20 | Hoffmann-La Roche Inc. | Three-dimensional structure-based humanization method |
WO2019025299A1 (en) | 2017-07-31 | 2019-02-07 | F. Hoffmann-La Roche Ag | Three-dimensional structure-based humanization method |
US10633435B2 (en) | 2018-03-05 | 2020-04-28 | Janssen Pharmaceutica Nv | Anti-PHF-tau antibodies and uses thereof |
WO2022201122A1 (en) | 2021-03-26 | 2022-09-29 | Janssen Biotech, Inc. | Humanized antibodies against paired helical filament tau and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
US20030039649A1 (en) | 2003-02-27 |
CN1671416B (en) | 2013-01-02 |
IL166244A0 (en) | 2006-01-15 |
US6881557B2 (en) | 2005-04-19 |
CA2491864A1 (en) | 2004-01-22 |
EP1539233A4 (en) | 2006-04-05 |
EP2298809A3 (en) | 2012-02-15 |
US20070003547A1 (en) | 2007-01-04 |
EP1539233B1 (en) | 2011-04-27 |
EP2298809A2 (en) | 2011-03-23 |
AU2002368077A2 (en) | 2004-02-02 |
US20110137014A1 (en) | 2011-06-09 |
JP2005538706A (en) | 2005-12-22 |
CN1671416A (en) | 2005-09-21 |
US20050261480A1 (en) | 2005-11-24 |
AU2002368077B2 (en) | 2010-03-04 |
EP1539233A1 (en) | 2005-06-15 |
US7709226B2 (en) | 2010-05-04 |
US7732578B2 (en) | 2010-06-08 |
MXPA05000511A (en) | 2005-09-30 |
AU2002368077A1 (en) | 2004-02-02 |
CA2491864C (en) | 2012-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002368077B2 (en) | Super humanized antibodies | |
US20050288491A1 (en) | Super-humanized antibodies against respiratory syncytial virus | |
EP1542725B1 (en) | Method of humanizing immune system molecules | |
EP0699755B1 (en) | Method for obtaining modified immunoglobulins with reduced immunogenicity of murine antibody variable domains, compositions containing them | |
EP2250199B1 (en) | Engineered anti-tslpr antibodies | |
CA2261026C (en) | Genetically engineered immunoglobulins with specificity for glycated albumin | |
JPH07504808A (en) | Humanized chimeric T cell antibody grafted with CDRs | |
JP2004073210A (en) | Modified antibody and product and process relating thereto | |
KR20140062127A (en) | Caninised antibodies and method for the production of same | |
US20040260068A1 (en) | Humanized chicken antibodies | |
JP2022545925A (en) | Anti-TFPI monoclonal antibody | |
Kaur | Overview of monoclonal antibodies | |
ES2370225T3 (en) | SUPERHUMANIZED ANTIBODIES. | |
JP2011115175A (en) | Super humanized antibody | |
MX2008005405A (en) | Horse: human chimeric antibodies. | |
WO2005014653A2 (en) | Humanized chicken antibodies | |
JP2012152223A (en) | Super humanized antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2491864 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002368077 Country of ref document: AU Ref document number: PA/a/2005/000511 Country of ref document: MX Ref document number: 166244 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004521391 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 44/KOLNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002752269 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028295986 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002752269 Country of ref document: EP |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |